KPTI
Karyopharm Therapeutics Inc.
$5.41
-$0.32(-5.58%)
31
Overall
--
Value
18
Tech
44
Quality
Market Cap
$54.28M
Volume
174.06K
52W Range
$3.51 - $16.95
Target Price
$17.60
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $250.0K | $154.0K | $1.6M | $30.3M | $40.9M | $108.1M | $209.8M | $157.1M | $146.0M | $145.2M | ||
| Total Revenue | $250.0K | $154.0K | $1.6M | $30.3M | $40.9M | $108.1M | $209.8M | $157.1M | $146.0M | $145.2M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | $2.7M | $3.4M | $5.2M | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $250.0K | $154.0K | $1.6M | $30.3M | $40.9M | $105.4M | $206.4M | $151.9M | $146.0M | $145.2M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-119.3M | $-110.9M | $-132.1M | $210.2M | $230.2M | $279.9M | $308.1M | $294.1M | $275.6M | $264.7M | ||
| Research & Development | $97.7M | $86.9M | $107.3M | $161.4M | $122.3M | $150.8M | $160.8M | $148.7M | $138.8M | $143.2M | ||
| Research Expense | $97.7M | $86.9M | $107.3M | $161.4M | $122.3M | $150.8M | $160.8M | $148.7M | $138.8M | $143.2M | ||
| Selling, General & Administrative | $21.6M | $23.9M | $24.9M | $48.8M | $105.4M | $126.4M | $143.8M | $145.4M | $131.9M | $115.4M | ||
| Selling & Marketing Expenses | -- | -- | -- | $48.8M | $105.4M | $126.4M | -- | -- | -- | -- | ||
| General & Administrative Expenses | $21.6M | $23.9M | $24.9M | $48.8M | $105.4M | $126.4M | $143.8M | $145.4M | $131.9M | $115.4M | ||
| Salaries & Wages | $-17.1M | $-22.3M | $-20.4M | $-17.3M | $2.4M | $2.7M | $29.8M | $35.4M | $21.7M | $18.4M | ||
| Depreciation & Amortization | $-634.0K | $-717.0K | $-713.0K | $-700.0K | $1.0M | $1.0M | $789.0K | $621.0K | -- | -- | ||
| Depreciation & Amortization | $-634.0K | $-717.0K | $-713.0K | $-700.0K | $-1.0M | $1.0M | $789.0K | $621.0K | -- | -- | ||
| Other Operating Expenses | $-119.3M | $-110.9M | $-132.1M | $-210.2M | $2.4M | $2.7M | $2.8M | $2.8M | $2.8M | $2.8M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-119.1M | $-110.7M | $-130.5M | $-179.9M | $-189.3M | $-171.8M | $-98.3M | $-142.2M | $-129.5M | $-119.4M | ||
| EBITDA | $-115.8M | $-107.5M | $-127.0M | $-173.7M | $-177.1M | $-167.9M | $-94.6M | $-139.3M | $-141.4M | $-32.2M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $2.5M | $15.6M | $27.1M | $26.0M | $25.0M | $23.8M | $37.4M | ||
| Intinc | $897.0K | $1.3M | $1.7M | $4.0M | $5.4M | $2.8M | $582.0K | $2.4M | $10.9M | $7.4M | ||
| Net Non-Operating Interest Income/Expense | $897.0K | $1.3M | $1.7M | $1.5M | $-10.2M | $-24.3M | $-25.5M | $-22.6M | $10.9M | $7.4M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | $500.0K | $90.0K | -- | -- | -- | ||
| Other Income/Expense | $2.0K | $-10.0K | $81.0K | $33.0K | $50.0K | $-206.0K | $85.0K | $-83.0K | $356.0K | $-73.1M | ||
| Other Special Charges | $-2.0K | $10.0K | $-81.0K | $-33.0K | $-50.0K | $206.0K | $-85.0K | $-83.0K | $-356.0K | $73.1M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-118.2M | $-109.4M | $-128.9M | $-175.9M | $-183.9M | $-168.8M | $-97.8M | $-139.9M | $-142.8M | $-38.9M | ||
| Pre-Tax Income | $-118.2M | $-109.4M | $-128.9M | $-178.4M | $-199.6M | $-196.0M | $-123.8M | $-164.9M | $-142.8M | $-76.4M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | $139.0K | $63.0K | $26.0K | $40.0K | $309.0K | $268.0K | $369.0K | $323.0K | $57.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-118.2M | $-109.6M | $-129.0M | $-178.4M | $-199.6M | $-196.3M | $-124.1M | $-165.3M | $-143.1M | $-76.4M | ||
| Net Income (Continuing Operations) | $-118.2M | $-109.6M | $-129.0M | $-178.4M | $-199.6M | $-196.3M | $-124.1M | $-165.3M | $-143.1M | $-76.4M | ||
| Net Income (Discontinued Operations) | $-118.2M | $-109.6M | $-129.0M | $-178.4M | $-199.6M | $-196.3M | $-124.1M | $-165.3M | $-143.1M | $-76.4M | ||
| Net Income (Common Stockholders) | $-118.2M | $-109.6M | $-129.0M | $-178.4M | $-199.6M | $-196.3M | $-124.1M | $-165.3M | $-143.1M | $-76.4M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-119.3M | $-110.9M | $-132.1M | $210.2M | $230.2M | $279.6M | $311.5M | $299.3M | $275.6M | $264.7M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $2.4M | $2.5M | $3.1M | $3.8M | $4.1M | $4.8K | $5.0M | $81.9M | $7.6M | $121.9K | ||
| Average Shares Outstanding (Diluted) | $2.4M | $2.5M | $3.1M | $3.8M | $4.1M | $4.8K | $5.0M | $81.9M | $7.6M | $126.8K | ||
| Shares Outstanding | $2.4M | $2.8M | $3.3M | $4.1M | $4.4M | $5.0M | $5.3M | $113.3M | $7.7M | $126.2M | ||
| Basic EPS | -- | -- | -- | -- | $-3.22 | $-2.72 | $-24.75 | $-2.02 | $-18.75 | $-0.63 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-24.75 | $-2.02 | $-18.75 | $-0.63 | ||
| Diluted EPS | $-49.8 | $-43.8 | $-42.15 | $-47.1 | $-48.3 | $-40.8 | $-24.75 | $-2.02 | $-18.75 | $-0.93 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-47.1 | $-48.3 | $-40.8 | -- | $-2.02 | $-18.75 | $-0.93 | ||
| OTHER METRICS | ||||||||||||
| Other Gand A | $21.6M | $23.9M | $24.9M | $48.8M | $105.4M | $126.4M | $143.8M | $145.4M | $131.9M | $115.4M | ||
| Rent And Landing Fees | $21.6M | $23.9M | $24.9M | $-2.5M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | -- | -- | -- | $48.8M | $105.4M | $126.4M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KPTI | $5.41 | -5.6% | 174.06K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Karyopharm Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW